EXPRESSION OF CALLA/CD10 ON HUMAN-MELANOMA CELLS

被引：36

作者：

CARREL, S

ZOGRAFOS, L

SCHREYER, M

RIMOLDI, D

机构：

[1] Ludwig Institute for Cancer Research, University of Lausanne, School of Medicine, University Hospital

来源：

MELANOMA RESEARCH | 1993年 / 3卷 / 05期

关键词：

CALLA/CD10; HUMAN MELANOMA; IMMUNOHISTOCHEMISTRY; MONOCLONAL ANTIBODY;

D O I：

10.1097/00008390-199310000-00003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The reactivity spectrum of an anti-CALLA/CD10 monoclonal antibody for cutaneous melanoma was analysed by immunohistochemistry in a series of lesions of different Breslow thickness. Similar proportions of small primary tumours, advanced primary tumours and metastatic lesions were found to express CALLA/CD10 (31-47%). However the proportion of stained cells within a given lesion increased with tumour progression. Up to 23% of the advanced primary lesions (>3.0 mm) showed 26-60% cells stained with the anti-CALLA/CD10 antibody and up to 14% of the metastatic lesions showed 76-100% stained cells. The expression of CALLA/CD10 was further analysed in 15 ocular melanoma lesions of different histiotype. All five spindle type lesions, three of six epitheloid and two of five mixed type lesions stained positively with the anti-CALLA/CD10 antibody. The percentage of stained cells within a given lesion varied from 30% to 100%. A total of 63% of the ocular melanomas and 38% of the cutaneous melanomas tested expressed CALLA/CD10. Experiments with cultured melanoma cell lines showed that the surface expression of CALLA/CD10 can be modulated in vitro by treatment with interleukin 2 (IL-2) and an adenosine 3',5'-cyclic monophosphate (analogue).

引用

页码：319 / 323

页数：5

共 23 条

[1] Greaves M.F., Brown G., Rapson N.T., Antisera to acute lymphoblastic leukemia cells, Clin Immunol Immunopathol, 4, pp. 67-84, (1975)
[2] Ritz J., Pesando J.M., Notis Mc Conatry J., Et al., A monoclonal antibody to human acute lymphoblastic leukaemia antigen, Nature, 283, (1980)
[3] Carrel S., Heumann D., Sekaly R.P., Characterization of a monoclonal antibody (A12) that defines a human acute lymphoblastic leukemia-associated differentiation antigen, Hybridoma, 2, pp. 149-160, (1983)
[4] Metzgar R.S., Borowitz M.J., Jones N.H., Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues, J Exp Med, 154, pp. 1249-1254, (1981)
[5] Carrel S., De Tribolet N., Gross N., Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells, Eur J Immunol, 12, pp. 347-354, (1982)
[6] Carrel S., Schmidt-Kessen A., Mach J.-P., Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines, J Immunol, 130, pp. 2456-2460, (1983)
[7] Shipp M.A., Tarr G.E., Chen C.-Y., CDlO/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung, Proc Natl Acad Set USA, 88, pp. 10662-10666, (1991)
[8] Letarte M., Vera S., Tran R., Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase, J Exp Med, 168, pp. 1247-1253, (1988)
[9] Kerr M.A., Kenny A.J., The purification and specificity of a neutral endopeptidase from rabbit kidney brush border, Biocbem J, 137, pp. 477-488, (1974)
[10] Gee N.S., Bowes N.A., Buck P., An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues, Biochem J, 228, pp. 119-126, (1985)

← 1 2 3 →